

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6028675

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ARGENX BVBA	10/16/2018
RECEIVING PARTY DATA	
Name:	STATEN BIOTECHNOLOGY B.V.
Street Address:	TRANSISTORWEG 5J
City:	NIJMEGEN
State/Country:	NETHERLANDS
Postal Code:	6534 AT
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16241407
CORRESPONDENCE DATA	
Fax Number:	(857)300-4001
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(857) 300-4000
Email:	leslie.roberts@lathropgpm.com, internalip@lathropgage.com
Correspondent Name:	LATHROP GPM LLP
Address Line 1:	28 STATE STREET
Address Line 2:	7TH FLOOR
Address Line 4:	BOSTON, MASSACHUSETTS 02109
ATTORNEY DOCKET NUMBER:	608719: SBW-003PCCON-4OF4
NAME OF SUBMITTER:	ANDREW T. WILKINS
SIGNATURE:	/Andrew T. Wilkins/
DATE SIGNED:	03/24/2020
Total Attachments: 5	
source=605141- SBW-008-1 - Executed Assignment - argenx to Staten Biotechnology#page1.tif	
source=605141- SBW-008-1 - Executed Assignment - argenx to Staten Biotechnology#page2.tif	
source=605141- SBW-008-1 - Executed Assignment - argenx to Staten Biotechnology#page3.tif	
source=605141- SBW-008-1 - Executed Assignment - argenx to Staten Biotechnology#page4.tif	
source=605141- SBW-008-1 - Executed Assignment - argenx to Staten Biotechnology#page5.tif	

ASSIGNMENT

WHEREAS, **argenx BVBA**, a corporation having its principal place of business at Industriepark 7, Zwijnaarde, Belgium, 9052, is the owner by assignment of certain rights, title and interest to the inventions described in the patent applications identified in Exhibit A hereto; and

WHEREAS, **Staten Biotechnology B.V.**, a corporation having its principal place of business at Transistorweg 5J, Nijmegen, 6534 AT, Netherlands, is desirous of acquiring all rights, title and interest in and to said inventions, said applications, and in and to any and all Letters Patents which may be granted for or upon said invention and applications in the United States of America and anywhere in the world.

NOW THEREFORE, to all whom it may concern, be it known that for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, **argenx BVBA** have sold, assigned and transferred, and hereby sell, assign and transfer unto the said **Staten Biotechnology B.V.**, the full and exclusive right, title and interest, throughout the world, in, to and under the following:

- (a) the inventions as set forth and described, for example, in the patent application specifications identified in Exhibit A;
- (b) all patent applications identified in Exhibit A;
- (c) any and all patent applications, including Patent Cooperation Treaty (PCT) applications, directed to the inventions as set forth and described, for example, in the patent application specifications identified in Exhibit A;
- (d) any and all refilings, divisions, continuations, and continuations-in-part of those patent applications;
- (e) any and all patents of the United States of America which may issue from any of the above items;
- (f) any and all reissue and reexamination certificates of those patents;
- (g) any and all applications for the inventions filed in any and all countries foreign to the United States of America;


- (h) any and all refilings, divisions, and continuations of those foreign-filed applications;
- (i) any and all patents, certificates, and registrations of countries foreign to the United States of America which may issue from those foreign-filed applications, refilings, divisions, and continuations;
- (j) any and all extensions of, and additions to, the foreign-filed applications and patents, certificates, and registrations related thereto;
- (k) the right to claim priority to any of the foregoing; and
- (l) any and all claims, causes of action, and damages for past, present, and future infringement or other unauthorized use of the above items, along with the right to sue and to collect damages and other relief from any and all parties.

argenx BVBA, further agrees that it will promptly execute and deliver to **Staten Biotechnology B.V.** or its legal representatives any and all papers, instruments, and affidavits required to apply for, obtain, maintain, issue, and enforce all of the items listed above.

All of the above shall be held and enjoyed by **Staten Biotechnology B.V.** and its successors, legal representatives, and assigns for their own use and benefit, for the full term for which the protections listed above may be granted, and **argenx BVBA** authorizes and requests the Commissioner of Patents and Trademarks of the United States and of all foreign countries to issue any Patents granted for said inventions, whether on an application for said invention set forth in Exhibit A, or on any subsequently filed provisional, non-provisional, divisional, continuation, continuation-in-part, reissue, or other related application, to **Staten Biotechnology B.V.**, its successors and assigns, as the assignee of their entire interest in said inventions and applications.

Assignor:

argenx BVBA


Signature

16 October 2018
Date:


Tui Jan Houweemans
Name and Title:

Signed in my presence and acknowledged to be an assignment of the application herein above referred to:

WITNESS

Gent, Belgium
Signed At (City/State)

Françoise Dewilde
Name


Signature

16 October 2018
Date

Assignee:

Staten Biotechnology B.V.

Hilde H. Steineger
Signature

10/10-2018
Date:

Hilde H. Steineger, CEO
Name and Title:

Signed in my presence and acknowledged to be an assignment of the application herein
above referred to:

WITNESS

OSLO, NORWAY
Signed At (City/State)

DAVID A. FRASER
Name

David Fraser
Signature

10/10-2018
Date

Jardine
Signature

Oct 26 2018

Date:

Paul DaSilva-Jardine, CSO
Name and Title:

Signed in my presence and acknowledged to be an assignment of the application herein
above referred to:

WITNESS

Guilford
Signed At (City/State)

karin reinisch
Name

Karin Marie Reinisch
Signature

Oct 26 2018
Date

Attorney Docket: 605141: SBW-008-1
Assigns to: Statens Biotechnology B.V.

Exhibit A

Assigned Patents and Patent Applications

U.S. Provisional Patent Application Serial No.: 62/579,449, filed October 31, 2017
U.S. Provisional Patent Application Serial No. 62/740,798, October 3, 2018
International Patent Application No. PCT/IB2017/054125, filed July 7, 2017
International Patent Application No. PCT/IB2018/052780, filed April 20, 2018